Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Advanced or Metastatic Solid Tumors 3Solid Tumors 2Sarcoma 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Solid Tumor 1Histiocytoma, Malignant Fibrous 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × envafolimab × Clear all
NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

3D Medicines

Phase 1/2 Recruiting
170 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡